Your browser is no longer supported. Please, upgrade your browser.
Settings
EIGR Eiger BioPharmaceuticals, Inc. daily Stock Chart
EIGR [NASD]
Eiger BioPharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.84 Insider Own0.40% Shs Outstand25.41M Perf Week-4.39%
Market Cap271.12M Forward P/E- EPS next Y-2.29 Insider Trans14.43% Shs Float24.06M Perf Month-4.13%
Income-60.70M PEG- EPS next Q-0.74 Inst Own75.90% Short Float2.38% Perf Quarter-3.61%
Sales- P/S- EPS this Y21.40% Inst Trans16.91% Short Ratio2.16 Perf Half Y-21.02%
Book/sh2.65 P/B4.03 EPS next Y-3.60% ROA-71.80% Target Price36.67 Perf Year-1.20%
Cash/sh3.38 P/C3.16 EPS next 5Y- ROE-121.20% 52W Range8.40 - 15.33 Perf YTD5.02%
Dividend- P/FCF- EPS past 5Y28.40% ROI- 52W High-30.40% Beta0.99
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin- 52W Low27.02% ATR0.48
Employees19 Current Ratio8.20 Sales Q/Q- Oper. Margin- RSI (14)45.35 Volatility3.84% 4.83%
OptionableYes Debt/Eq0.00 EPS Q/Q-6.90% Profit Margin- Rel Volume0.32 Prev Close10.74
ShortableYes LT Debt/Eq0.59 EarningsAug 09 AMC Payout- Avg Volume265.45K Price10.67
Recom1.00 SMA20-2.34% SMA50-1.53% SMA200-9.67% Volume84,309 Change-0.65%
Jun-26-19Initiated Citigroup Buy $22
Jan-29-19Initiated Robert W. Baird Outperform $47
May-09-18Initiated B. Riley FBR, Inc. Buy $24
Jan-03-18Initiated Ladenburg Thalmann Buy $32
Oct-19-17Initiated ROTH Capital Buy $35
Jun-21-17Resumed Wedbush Outperform $28 → $34
Jul-18-19 09:20AM  Small Peninsula biotech targets big impact on deadly childhood aging disease American City Business Journals
Jul-11-19 12:42PM  Need To Know: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Insiders Have Been Buying Shares Simply Wall St.
Jul-08-19 09:00AM  What Makes Eiger BioPharma (EIGR) a New Buy Stock Zacks +12.97%
Jun-20-19 07:08PM  Hedge Funds Have Never Been This Bullish On Eiger BioPharmaceuticals, Inc. (EIGR) Insider Monkey
Jun-18-19 07:31AM  The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
Jun-17-19 04:16PM  Eiger Announces Breakthrough Therapy Designation Granted by FDA for Avexitide for Treatment of Post-Bariatric Hypoglycemia (PBH) PR Newswire
Jun-10-19 08:00AM  Eiger Appoints Industry Veteran and Regulatory Affairs Expert Mark Mannebach, PhD, RPh as Vice President of Global Regulatory Affairs PR Newswire
Jun-05-19 08:00AM  Eiger Appoints Jeysen Yogaratnam, MB.BCh, BAO, MRCSEd, PhD, MBA, Vice President of Global HDV Clinical Development PR Newswire
May-30-19 08:00AM  Eiger BioPharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference PR Newswire
May-17-19 04:05PM  Eiger BioPharmaceuticals Announces Transition of Chief Operating Officer and Executive Medical Officer PR Newswire
May-09-19 05:04PM  Eiger BioPharma: 1Q Earnings Snapshot Associated Press
04:01PM  Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update PR Newswire
Apr-30-19 08:00AM  Eiger to Present at ChinaBio® Partnering Forum 2019 PR Newswire
Apr-26-19 02:43PM  Do Institutions Own Shares In Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)? Simply Wall St.
Apr-23-19 03:50PM  Weekly CFO Buys Highlight GuruFocus.com
Apr-17-19 10:53PM  Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock PR Newswire -5.72%
04:01PM  Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
Apr-15-19 08:00AM  Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors PR Newswire
Apr-11-19 04:05PM  Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress 2019 PR Newswire
Mar-26-19 08:00AM  Eiger BioPharmaceuticals to Participate in Conferences in April PR Newswire
Mar-25-19 01:30PM  Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019 PR Newswire
Mar-20-19 08:00AM  Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 PR Newswire
Mar-15-19 09:04AM  What Makes Eiger BioPharma (EIGR) a New Buy Stock Zacks
Mar-14-19 04:19PM  Eiger BioPharma: 4Q Earnings Snapshot Associated Press
Mar-13-19 08:00AM  Eiger Late-Breaker Oral Presentation of Peginterferon Lambda Phase 2 LIMT Study at The International Liver Congress 2019 PR Newswire
Mar-11-19 08:00AM  Eiger BioPharmaceuticals Management Team to Present and Participate in Jefferies HBV Investor Summit PR Newswire
Mar-08-19 07:37PM  [$$] Five Best: Susan Froderberg on Extraordinary Mountain Ascents The Wall Street Journal
Mar-04-19 07:00AM  Clinigen and Eiger BioPharmaceuticals Launch Worldwide Managed Access Program for Lonafarnib for Patients with Progeria and Progeroid Laminopathies Business Wire
Feb-27-19 08:00AM  Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer PR Newswire
Feb-06-19 08:00AM  Eiger BioPharmaceuticals Announces Patent Protection for Lonafarnib Boosted with Ritonavir for Treatment of Hepatitis Delta Virus Infection in Europe and Japan PR Newswire
Feb-04-19 08:00AM  Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans PR Newswire
Jan-07-19 08:00AM  Eiger BioPharmaceuticals Appoints Regulatory Expert and Industry Veteran Christine Murray, MS, RAC to its Board of Directors PR Newswire +8.79%
Dec-31-18 07:30AM  Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Dec-21-18 09:25AM  Have Insiders Been Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Shares? Simply Wall St. -5.62%
Dec-19-18 08:00AM  Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies PR Newswire -5.34%
Dec-18-18 08:00AM  Eiger Announces PRIME Designation Granted by European Medicines Agency for Lonafarnib for Treatment of Hepatitis Delta Virus Infection PR Newswire -5.75%
Dec-17-18 08:00AM  Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib for Treatment of Hepatitis Delta Virus (HDV) Infection PR Newswire
Dec-11-18 02:30PM  Eiger BioPharmaceuticals Reports on 2018 R&D Day PR Newswire
Dec-04-18 08:00AM  Eiger BioPharmaceuticals to Host R&D Day in New York City PR Newswire
07:59AM  The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO Benzinga
Dec-03-18 04:05PM  Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer PR Newswire +5.56%
08:00AM  Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies PR Newswire
Nov-23-18 08:25AM  Analysis: Positioning to Benefit within Artisan Partners Asset Management, Gamco Investors, Eiger BioPharmaceuticals, Waddell & Reed Financial, AmpliPhi Biosciences, and Limbach Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +8.98%
Nov-19-18 08:00AM  Eiger to Participate in Piper Jaffray Healthcare Conference PR Newswire
Nov-09-18 08:23AM  Eiger BioPharma: 3Q Earnings Snapshot Associated Press -6.19%
08:00AM  Eiger Bio Reports Third Quarter 2018 Financial Results PR Newswire
Oct-23-18 09:00AM  Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PR Newswire
08:35AM  The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares Benzinga
Oct-22-18 04:01PM  Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire -10.01%
08:00AM  Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019 PR Newswire
Oct-18-18 08:00AM  Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference PR Newswire
07:56AM  The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs Benzinga
Oct-17-18 04:05PM  Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection PR Newswire +7.36%
08:15AM  The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise Benzinga
Oct-16-18 04:05PM  Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH) PR Newswire +7.09%
04:05PM  Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint PR Newswire
Sep-25-18 08:00AM  Eiger BioPharmaceuticals to Participate in Investor Conferences PR Newswire
Sep-24-18 08:00AM  Eiger Announces FDA Guidance on HDV Phase 3 Study Design: Primary Endpoint Established; D-LIVR Study Initiating Q4 2018 PR Newswire
Aug-27-18 08:00AM  Eiger BioPharmaceuticals to Participate in Investor Conferences PR Newswire
Aug-13-18 08:00AM  Eiger BioPharmaceuticals Announces Completion of Enrollment in Phase 2 PREVENT Study of Avexitide (formerly Exendin 9-39) in Patients Suffering from Post-Bariatric Hypoglycemia PR Newswire
Aug-10-18 08:09AM  Eiger BioPharma: 2Q Earnings Snapshot Associated Press
08:00AM  Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results PR Newswire
Aug-07-18 08:00AM  Eiger BioPharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-06-18 08:00AM  Eiger BioPharmaceuticals Announces First Patient Enrolled in Phase 2 LIFT Study of Pegylated Interferon Lambda in Combination with Ritonavir-Boosted Lonafarnib at National Institutes of Health PR Newswire
Jul-31-18 08:00AM  Eiger BioPharmaceuticals Announces Notice of Allowance for U.S. Patent Covering a Broad Range of Ritonavir-Boosted Lonafarnib Dosing Regimens for Treatment of Hepatitis Delta Virus Infection PR Newswire
Jul-19-18 07:26AM  Eiger BioPharmaceuticals (EIGR) Enters Oversold Territory Zacks
05:51AM  Eiger BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-04-18 08:00AM  Eiger Announces HDV Phase 2 Program Oral Presentation and Investigator / Key Opinion Leader Reception for Planned HDV Phase 3 D-LIVR Study at Global Hepatitis Summit 2018 PR Newswire +8.00%
May-30-18 08:00AM  Eiger BioPharmaceuticals to Present at Jefferies 2018 Global Healthcare Conference PR Newswire
May-24-18 09:05AM  Eiger BioPharmaceuticals Prices Previously Announced Public Offering of Common Stock PR Newswire -6.09%
08:37AM  Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings Benzinga
May-23-18 04:15PM  Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock PR Newswire
May-18-18 08:10AM  Todays Research Reports on Stocks to Watch: Eiger BioPharmaceuticals and Nektar Therapeutics ACCESSWIRE -17.26%
May-16-18 08:00AM  Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals PR Newswire +8.22%
08:00AM  Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF) PR Newswire
May-11-18 08:09AM  Eiger BioPharma: 1Q Earnings Snapshot Associated Press +8.11%
08:00AM  Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results PR Newswire
Apr-17-18 10:31AM  Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress 2018 PR Newswire
Apr-02-18 08:00AM  Eiger BioPharmaceuticals to Participate in Conferences in April PR Newswire
Mar-29-18 07:59PM  What Should We Expect From Eiger BioPharmaceuticals Incs (NASDAQ:EIGR) Earnings In The Next Couple Of Years? Simply Wall St. +5.35%
Mar-26-18 08:00AM  Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia PR Newswire
Mar-23-18 07:00AM  Wired News FDA Permitted a Single Registration Trial Assessing Eiger BioPharmas Lonafarnib in HDV to Support NDA Filing ACCESSWIRE
Mar-21-18 08:00AM  Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program PR Newswire
Mar-12-18 08:13AM  Eiger BioPharma reports 4Q loss Associated Press -8.21%
08:00AM  Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire
Mar-06-18 08:00AM  Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March PR Newswire
Mar-05-18 08:00AM  Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress Meeting PR Newswire
Feb-06-18 08:00AM  Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February PR Newswire
Jan-23-18 11:30AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 InvestorPlace
Jan-19-18 08:54AM  These Two Biotechs Just Reported Key Data Market Exclusive
Jan-16-18 10:45AM  Why Eiger BioPharma Shares Are Getting Crushed 24/7 Wall St. -49.37%
08:54AM  Eiger shares plummet 40% after phase 2 trial failure MarketWatch
08:00AM  Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint PR Newswire
Jan-08-18 08:00AM  Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors PR Newswire
Jan-04-18 08:00AM  Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients PR Newswire
Jan-03-18 08:00AM  Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer PR Newswire
Jan-02-18 08:00AM  Eiger BioPharmaceuticals to Present at Biotech Showcase 2018 PR Newswire
Dec-22-17 08:57AM  Why Eiger BioPharmaceuticals (EIGR) Could Be Positioned for a Surge Zacks
Nov-13-17 08:00AM  Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference PR Newswire
Nov-09-17 08:39AM  Eiger BioPharma reports 3Q loss Associated Press
Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dietz Thomas JohnDirectorApr 23Buy11.105,00055,49520,000Apr 23 06:53 PM
Dietz Thomas JohnDirectorApr 22Buy11.055,00055,25015,000Apr 22 09:34 PM
Ryali SriramChief Financial OfficerApr 22Buy11.081,25013,8531,250Apr 22 09:34 PM
Patton Stephana EileneSee RemarksApr 22Buy11.031,00011,0304,000Apr 22 09:31 PM
Cory David APresident and CEOFeb 04Buy11.263433,86266,346Apr 26 04:54 PM
Cory David APresident and CEOFeb 04Buy14.132273,20858,678Feb 06 07:23 PM
Dietz Thomas JohnDirectorDec 20Buy9.985,00049,90010,000Dec 20 08:29 PM
Dietz Thomas JohnDirectorDec 06Buy11.265,00056,3005,000Dec 10 04:05 PM
Mayer Eldon C. IIIDirectorNov 29Buy10.214,00040,84025,000Nov 30 02:26 PM
Mayer Eldon C. IIIDirectorNov 27Buy9.927,50074,40815,000Nov 28 08:51 PM
Mayer Eldon C. IIIDirectorNov 26Buy9.757,50073,1437,500Nov 28 08:51 PM
INTERWEST PARTNERS X LP10% OwnerOct 18Sale12.06237,2652,862,3211,362,327Oct 22 04:33 PM